
Opinion|Videos|February 28, 2025
CheckMate-9ER: Updates Presented at ASCO 2025
Panelists discuss how the latest progression-free survival, overall survival, and overall response rate data presented at ASCO 2025 demonstrate significant advancements in treatment efficacy across multiple tumor types.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
2
Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up
3
CheckMate 9LA Data Push Toward Dual Checkpoint Blockade in PD-L1–Negative NSCLC
4
Thoracic Radiotherapy Added to Atezolizumab Raised Toxicity in SCLC
5


























